[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591619":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":21,"locations":7,"responsibleParty":27,"collaborators":7,"id":29,"slug":7,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":48,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":7},{"fullName":5,"class":6},"Microvention-Terumo, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Flow Re-Direction Endoluminal Device System(FRED)","Flow Diverter (FD) devices are developed based on reconstructing the parent artery's lumen. FDs are designed with a denser mesh compared to conventional intracranial stents. By covering the aneurysm neck, these stents redirect blood flow away from the aneurysm, promoting intra-aneurysmal flow stagnation and subsequent thrombosis formation. Currently, FDs are primarily used for the treatment of wide-neck aneurysms.",[14,18],{"name":15,"affiliation":16,"role":17},"Tianxiao Li","Henan Provincial People's Hospital","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":20,"role":17},"Sheng Guan","The First Affiliated Hospital of Zhengzhou University",[22],{"name":23,"role":24,"phone":25,"phoneExt":7,"email":26},"Brook Li","CONTACT","86 138 918 55337","brook.li@microvention.com",{"type":28,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100591619",false,"NCT06982781","FRED Retrospective Study of Intracranial Aneurysms Treatment","A Retrospective Post-Market Clinical Study of the Flow Re-Direction Endoluminal Device System in the Treatment of Intracranial Aneurysms","FRED","Inclusion Criteria:\n\n* People in China mainland who have been treated with FRED. The patients for whom clinical data are available\n\nExclusion Criteria:\n\n* Patients who met the inclusion criteria at all time points were required to be included in the study. Therefore, no specific exclusion criteria were set.","ALL","18 Years","90 Years",{"count":40,"type":41},2000,"ESTIMATED","OBSERVATIONAL","To evaluate the long-term safety and efficacy of Flow Re-Direction Endoluminal Device System (FRED) in the treatment of intracranial aneurysms in the post-market environment",[45],"Intracranial Aneurysm",[47],"Intracranial Aneurysms","NOT_YET_RECRUITING","2025-05-20",{"date":51,"type":52},"2025-05-21","ACTUAL",{"date":54,"type":41},"2025-05",{"date":56,"type":41},"2027-05-06",{"name":5,"class":6}]